← All Cellectar Biosciences, INC filings

Cellectar Biosciences, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
CLRB
Cellectar Biosciences, INC
10-K/A: Cellectar Biosciences Files 10-K/A Amendment
Cellectar Biosciences filed an amendment to its 2025 Annual Report to provide required Part III disclosures.
NASDAQ
CLRB
Cellectar Biosciences, INC
10-K: Cellectar Biosciences Faces Going Concern Doubt Amid R&D Focus
Cellectar Biosciences reports significant losses and a going concern warning for 2025, despite positive clinical data for iopofosine I 131 and other PDC programs.
NASDAQ
CLRB
Cellectar Biosciences, INC
10-K: Cellectar Biosciences Reports 2024 Results, Highlights Progress in Cancer-Targeting PDC Platform
Cellectar Biosciences' 2024 10-K filing details the company's focus on developing phospholipid drug conjugates (PDCs) for targeted cancer treatment and provides an update on its clinical programs and financial status.
NASDAQ
CLRB
Cellectar Biosciences, INC
10-K/A: Cellectar Biosciences Restates Financials Following Accounting Errors, Shares Tumble
Cellectar Biosciences has restated its financial statements for fiscal years 2022 and 2023 due to accounting errors related to warrants and preferred stock, leading to material weaknesses in internal controls.
NASDAQ
CLRB
Cellectar Biosciences, INC
10-K/A: Cellectar Biosciences Files Amended 10-K to Include Omitted Exhibits and Correct Errors
Cellectar Biosciences has filed an amendment to its annual report on Form 10-K to include previously omitted exhibits and correct a minor error.
NASDAQ
CLRB
Cellectar Biosciences, INC
10-K: Cellectar Biosciences Reports Positive Phase 2 Trial Results for Iopofosine in Waldenstrom's Macroglobulinemia
Cellectar Biosciences' pivotal Phase 2 study of iopofosine in relapsed/refractory Waldenstrom's macroglobulinemia met its primary endpoint with a 61% major response rate.